多发性骨髓瘤患者外周血清中microRNA-181a和microRNA-20a表达水平的检测及其临床意义

doi:10.13481/j.1671-587x.20150336

吉林大学学报(医学版) ›› 2015, Vol. 41 ›› Issue (03): 625-630.doi: 10.13481/j.1671-587x.20150336

多发性骨髓瘤患者外周血清中microRNA-181a和microRNA-20a表达水平的检测及其临床意义

彭晶¹, 袁瑞丽², 王晓琴², 吴锋³, 郭炫²

1. 西安交通大学医学院, 陕西西安 710061;
2. 西安交通大学医学院第一附属医院检验科, 陕西西安 710061;
3. 西安交通大学医学院医学研究生教学实验中心, 陕西西安 710061

收稿日期:2014-08-31 发布日期:2015-08-01
通讯作者: 郭炫,主任技师,硕士研究生导师(Tel:029-85323702,E-mail:guox9512@163.com) E-mail:guox9512@163.com
作者简介:彭晶(1986-),女,山西省稷山县人,检验技师,在读医学硕士,主要从事生化免疫学方面的研究。
基金资助:
陕西省科技厅科技研究发展计划项目资助课题(2014K11-01-02-03)

Detection of expression levels of microRNA-181a and microRNA-20a in serum of patients with multiple myeloma and its clinical significance

PENG Jing¹, YUAN Ruili², WANG Xiaoqin², WU Feng³, GUO Xuan²

1. School of Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China;
2. Department of Clinical Laboratory, First Affiliated Hospital, School of Medical Sciences, Xi'an Jiaotong niversity, Xi'an 710061, China;
3. Department of Medical Graduate Students Teaching Experiment Center, School of Medical Sciences, Xi'an Jiaotong University, Xi'an 710061, China

Received:2014-08-31 Published:2015-08-01

摘要/Abstract

摘要：

目的:检测多发性骨髓瘤(MM)患者外周血血清中microRNA-181a和microRNA-20a表达水平,探讨microRNA-181a和microRNA-20a在MM发病过程中的临床意义。方法:选取2013年1月—2014年5月西安交通大学第一附属医院血液科住院患者作为病例组研究对象,其中MM组32例,其他血液病组12例,所有研究对象均符合《血液病诊断和疗效标准》中诊断标准且均经临床医师确诊,并排除心、肺、肝脏等其他器官衰竭且病情稳定者。同时选取同期20名健康体检者作为正常对照组。收集各组研究对象的外周血标本,采用实时荧光定量PCR方法检测血清中microRNA-181a和microRNA-20a表达情况,同步检测血清β2微球蛋白(β2-MG)水平、乳酸脱氢酶(LDH)活性、白蛋白(ALB)水平、游离轻链(FLC)水平及M蛋白百分比,并比较其差异。结果:MM组、其他血液病组和正常对照组研究对象血清中 microRNA-181a和microRNA-20a表达水平分别为0.0452和5.879、0.000和0.072、0.004和1.159,3组间比较差异有统计学意义(H=15.218,9.891;P=0.000,0.007)。MM组患者血清中microRNA-181a和microRNA-20a表达水平与正常对照组比较差异有统计学意义(Z=-2.702,-1.979;P=0.005,0.048),MM组与其他血液病组比较差异也有统计学意义(Z=-3.163,-2.722;P=0.001,0.005);microRNA-181a和microRNA-20a表达水平均与M蛋白百分比呈正相关关系(r=0.574,0.739;P=0.032,0.003);miR-181a表达水平与肿瘤负荷指标β2-MG和FLC呈正相关关系 (r=0.552,0.780;P=0.041,0.001)。结论:MM患者血清中microRNA-181a和microRNA-20a高表达,其可能参与MM的发病过程,有望成为MM诊断标志物;其中microRNA-181a可能作为判断MM患者预后不良的指标。

关键词: microRNA-181a, microRNA-20a, 多发性骨髓瘤, 实时聚合酶链反应

Abstract:

Objective To investigate the expression levels of serum microRNA-181a and microRNA-20a in the patients with multiple myeloma (MM), and to explore the clinical significances of microRNA-181a and microRNA-20a in the occurrence and development of MM. Methods 32 patients with M and 12 patients with other blood diseases, from Department of Hematology of First Affiliated Hospital, School of Medical Sciences, Xi'an Jiaotong University, during 2013.01-2014.05, were chosen.All the subjects accorded with the diagnostic criteria from Blood Disease Diagnosis and Curative Effect of Standard, excluding anybody who was in a stable condition with other organ failure such as heart, lung, and liver.And at the same time, 20 healthy subjects were selected as control group.The expression levels of microRNA-181a and microRNA-20a in serum of the patients with MM, the patients with other disease and healthy individuals were examined by Real-time polymerase chain reaction (Real-time PCR).The serum β2 microglobulin (β2- MG) levels, lactate dehydrogenase (LDH) activities, albumin (ALB) levels, free light chain (FLC) levels and M protein percentages were detected at the same time in three groups, and then the differences were compared. Results The expression levels of serum microRNA-181a and microRNA-20a in three groups were 0.0452 and 5.879, 0.000 and 0.072, 0.004 and 1.159, respectively;the differences showed statistically signiifcance(H=15.218, 9.891;P=0.000, 0.007).The differences between MM group and normal control group were statistically significant (Z=-2.702, -1.979;P=0.005, 0.048) and the differences between MM group and other blood diseases group were also statistically significant (Z=-3.163, -2.722;P=0.001, 0.005).The expression levels of microRNA-181a and microRNA-20a were positively correlated with the M protein percentage(r=0.574, 0.739;P=0.032, 0.003);the expression level of microRNA-181a was positively related with the serum β2-MG and serum free FLC levels(r=0.552, 0.780;P=0.041, 0.001). Conclusion The microRNA-181a and microRNA-20a highly express in the serum of the patients with MM, which suggests that microRNA-181a and microRNA-20a might play a role in the development of MM and they may become the diagnosis markers of MM;microRNA-181a is expected to be an index to predict the poor prognosis of MM.

Key words: microRNA-181a, microRNA-20a, multiple myeloma, Real-time polymerase chain reaction

中图分类号:

R733.3

彭晶, 袁瑞丽, 王晓琴, 吴锋, 郭炫. 多发性骨髓瘤患者外周血清中microRNA-181a和microRNA-20a表达水平的检测及其临床意义[J]. 吉林大学学报(医学版), 2015, 41(03): 625-630.

PENG Jing, YUAN Ruili, WANG Xiaoqin, WU Feng, GUO Xuan. Detection of expression levels of microRNA-181a and microRNA-20a in serum of patients with multiple myeloma and its clinical significance[J]. Journal of Jilin University Medicine Edition, 2015, 41(03): 625-630.

参考文献

[1] Turner ML, Schnorfeil FM, Brocker T.MicroRNAs regulate dendritic cell differentiation and function[J].J Immunol, 2011, 187 (8):3911-3917.

[2] Leone E, Morelli E, Tassone P, et al.Targeting microRNA-21 inhibits in vitro and in vivo multiple myeloma cell growth[J].Clin Cancer Res, 2013, 19(8):2096-2106.

[3] Pichiorri F, Suh SS, Rocci A, et al.Downregulation of p53-inducible microRNAs 192, 194and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development[J].Cancer Cell, 2010, 18(4):367-381.

[4] Zhang W, Wang YE, Zhang Y, et al.Global epigenetic regulation of microRNAs in multiple myeloma[J].PLoS One, 2014, 9(10):e110973.

[5] Pons A, Nomdedeu B, Navarro A, et al.Hematopoiesis-related microRNA expression in myelodysplastic syndromes[J].Leuk Lymphoma, 2009, 50(11):1854-1859.

[6] Chen CZ, Li L, Lodish HF, et al.MicroRNAs modulate hematopoietic lineage differentiation[J].Science, 2004, 303(5653):83-86.

[7] Yyusnita Y, Norsiah MD, Zakiah I, et al.MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray[J].Malays J Pathol, 2012, 34(2):133-143.

[8] Lionetti M, Agnelli L, Mosca L, et al.Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated microRNA expression associated with allelic imbalances and gene expression profiles[J].Genes Chromosomes Cancer, 2009, 48(6):521-531.

[9] Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al.Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders[J].Blood Cancer J, 2012, 2(1):e53.

[10] Xiao C, Srinivasan L, Calado DP, et al.Lymphoproliferative disease and autoimmunity in mice with increased microRNA17-92 expression in lymphocytes[J].Nature Immunol, 2008, 9(4):405-414.

[11] Lee SK, Calin GA.Non-coding RNAs and cancer:new paradigms in oncology[J].Discov Med, 2011, 11(58):245-254.

[12] Yang X, Liang L, Zhang XF, et al.MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway[J].Hepatology, 2013, 58(1):158-170.

[13] Ahmad A, Maitah MY, Ginnebaugh KR, et al.Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating microRNAs[J].J Hematol Oncol, 2013, 6(1):77-86.

[14] Nishida N, Nagahara M, Sato T, et al.Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic microRNA clusters[J].Clin Cancer Res, 2012, 18(11):3054-3070.

[15] Song SD, Zhou J, Zhou J, et al.MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma[J].Oncol Lett, 2013, 6(4):953-959.

[16] Cui B, Chen L, Zhang S, et al.MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia[J].Blood, 2014, 124(4):546-554.

[17] Qu X, Zhao M, Wu S, et al.Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma[J].Med Oncol, 2014, 31(10):e219.

[18] Luo X, Gu J, Zhu R, et al.Integrative analysis of differential miRNA and functional study of microRNA21 by seed-targeting inhibition in multiple myeloma cells in response to berberine[J].BMC Syst Biol, 2014, 8(1):82-91.

多发性骨髓瘤患者外周血清中microRNA-181a和microRNA-20a表达水平的检测及其临床意义

Detection of expression levels of microRNA-181a and microRNA-20a in serum of patients with multiple myeloma and its clinical significance

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

Metrics

本文评价

推荐阅读 0

[1]	王冲, 郝铮, 刘伟明, 赵丛海, 张金男. 颅脑损伤后硬膜外血肿骨化1例报告及文献复习[J]. 吉林大学学报(医学版), 2018, 44(03): 628-630.
[2]	黄琦, 沙辉, 陈龙, 吕龙龙, 徐声鸣, 张泽天, 赵松, 靳凤艳, 牛丰. 多发性骨髓瘤和慢性淋巴细胞白血病患者血浆lncRNA MALAT1、LincRNA-p21和GAS5的表达水平及其诊断意义[J]. 吉林大学学报(医学版), 2018, 44(02): 339-345.
[3]	甄永占，纪春梅，赵毓芳，闫丰，刘学军，王梅梅，徐爱军. 硼替佐米通过内质网应激途径增强力达霉素对人多发性骨髓瘤细胞SKO-007凋亡诱导作用 [J]. 吉林大学学报(医学版), 2013, 39(6): 1206-1210.
[4]	王雪梅\| 崔久嵬\|肖中平\|陈琳\|高鹏\|付堃\|韩梅\|王冠军. MPT与MP方案治疗老年多发性骨髓瘤的疗效比较[J]. J4, 2012, 38(5): 999-1002.
[5]	姚程，刘峰，姜振宇，康丽花. VAD、M₂和MP化疗方案治疗多发性骨髓瘤的疗效评价[J]. J4, 2007, 33(1): 167-169.